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ABSTRACT
Background: Recent studies have examined sugar-sweetened soda
consumption in relation to early markers of kidney disease, but to
date there have been no investigations of whether sugar-sweetened
beverage consumption affects preexistent chronic kidney disease
(CKD).
Objective: This prospective cohort study of 447 participants in the
Multi-Ethnic Study of Atherosclerosis (MESA) with preexistent
CKD examined the association between sugar-sweetened beverage
consumption (,1 drink/wk, 1–6 drinks/wk, and 1 drink/d) and
progression of CKD.
Design: b-Coefficients for continuous outcomes of changes in esti-
mated glomerular filtration rate (eGFR) and urinary albumin to
creatinine ratio (UACR) were calculated by using linear regression.
Odds ratios for binary outcomes of accelerated decline in eGFR,
defined as .2 mL  min21  1.73 m22 per year, and clinically sig-
nificant progression of albuminuria (defined as attainment of UACR
30 mg/g for participants without microalbuminuria at visit 1 or
a 25% increase in UACR for participants with baseline micro-
albuminuria) were evaluated by using logistic regression.
Results: The mean (6SD) baseline eGFR was 52 6 6 mL  min21 
1.73 m22 per year, and median baseline UACR was 6.3 mg/g (in-
terquartile range: 3.5–17.6). Univariate and multivariate analyses
showed no association between sugar-sweetened beverage con-
sumption and rate of eGFR decline or changes in urinary albumin
to creatinine ratio. The multivariate odds ratios comparing partic-
ipants who drank 1 sugary beverage daily with those who drank
1 beverage weekly were 0.62 (95% CI: 0.27, 1.41) for accelerated
eGFR decline and 1.51 (95% CI: 0.49, 4.62) for clinically signifi-
cant progression of albuminuria.
Conclusion: A higher consumption of sugar-sweetened beverages
was not associated with disease progression, on the basis of either
eGFR or the urinary albumin to creatinine ratio, in MESA partic-
ipants with preexistent CKD. Am J Clin Nutr 2009;90:1172–8.
INTRODUCTION
Chronic kidney disease (CKD) is associated with premature
mortality, decreased quality of life, and increased health care
expenditures. CKD is typically progressive in nature: patients
with CKD stage 3, the least advanced stage defined from glo-
merular filtration rate (GFR) alone, on average experience a
yearly decline in GFR of 1 mL  min21  1.73 m22 (1). However,
the progression of CKD often follows an unpredictable course,
even when the etiology is well defined, as in diabetic nephrop-
athy (2). Some patients progress very slowly, whereas others
progress quite rapidly, and the reasons for this variability are not
completely understood.
Treatment factors (eg, successful control of diabetes), genetics
(eg, family history of end-stage renal disease), and environmental
cues (eg, exposure to toxins) likely play important roles in de-
termining the rate of renal decline, as do immutable factors such
as age and sex. Diet may also affect renal function. Nephrologists
often recommend salt restriction, which should help with blood
pressure and fluid status, andmay advocate for protein restriction,
although the benefit of this intervention for CKD remains
controversial.
Recently, consumption of sugar-sweetened sodas has been
linked, by cross-sectional analyses, to elevated serum creatinine
(3) and microalbuminuria (4). However, longitudinal studies
provide stronger evidence for or against diet-related diseases. We
therefore examined the relation between sugar-sweetened bev-
erage consumption and progression of established CKD using
data from the Multi-Ethnic Study of Atherosclerosis (MESA).
We hypothesized that daily sugar-sweetened beverage con-
sumption is inversely associated with changes in GFR and
positively related to changes in urinary albumin excretion in
adults with preexistent CKD (estimated GFR ,60 mL  min21 
1.73 m22).
1 From the Department of Medicine, Division of Nephrology, Columbia
University Medical Center, New York, NY (ASB); the Department of Bio-
statistics, University of Washington School of Public Health, Seattle, WA
(RK); the Departments of Epidemiology and Nutrition (KH), University of
North Carolina, Gillings School of Global Public Health, Chapel Hill, NC;
the Department of Preventive Medicine and Epidemiology, Stritch School of
Medicine, Loyola University Chicago, Maywood, IL (DAS); the Division of
Public Health Sciences, Wake Forest University Health Sciences, Winston-
Salem, NC (GLB); and the Department of Medicine, Division of Nephrology
and Hypertension, University of North Carolina School of Medicine, Chapel
Hill, NC (PJK).
2 Supported by contracts N01-HC-95159 through N01-HC-95169 from
the National Heart, Lung, and Blood Institute.
3 Address reprint requests and correspondence to AS Bomback, Columbia
University, Division of Nephrology, 622 West 168th Street, PH 4-124, New
York, NY 10032. E-mail: asb68@columbia.edu.
Received May 21, 2009. Accepted for publication August 17, 2009.
First published online September 9, 2009; doi: 10.3945/ajcn.2009.28111.
1172 Am J Clin Nutr 2009;90:1172–8. Printed in USA.  2009 American Society for Nutrition
SUBJECTS AND METHODS
Participants and study design
MESA was established by the US National Heart, Lung, and
Blood Institute to examine the determinants of subclinical car-
diovascular disease measures and their associations with car-
diovascular disease outcomes. A full description of MESA is
available elsewhere (5). A total of 6814 men and women from 4
ethnic groups (white, African American, Hispanic, and Chinese)
aged 45–84 y were recruited from 6 field centers: Baltimore, MD;
Chicago, IL; Forsyth County, NC; Los Angeles, CA; New York,
NY; and St Paul, MN. The MESA protocol was approved by the
institutional review boards of all participating centers, and in-
formed consent was obtained from all participants.
Visit 1 (baseline examination) for the MESA cohort took place
between July 2000 and September 2002 and was followed by two
18-mo examination periods and an additional 2-y examination
period. Data from visits 1, 3, and 4 (’5-y duration) were used
for this analysis. To create a subcohort of subjects with CKD,
we included participants whose estimated GFR at visit 1 was,60
mL  min21  1.73 m22 and remained,60 mL min21  1.73 m22
at visit 3 and/or visit 4. This definition for CKD, based on re-
peated rather than single measurements of creatinine, best cap-
tured the K/DOQI (Kidney Disease Outcomes Quality Initiative)
guidelines on classifying CKD as a reduced GFR for 3 mo (6).
Outcomes
The outcomes of interest were changes in estimated GFR
(eGFR) and albuminuria. eGFR was calculated from serum
creatinine concentrations measured at visits 1, 3, and 4 by using
the Modification of Diet in Renal Disease Study equation (7):
eGFR ¼ 1863 ðserum creatinineÞ1:154 3 ðageÞ0:203
3 1:212ðif blackÞ3 0:742ðif femaleÞ ð1Þ
All MESA creatinine values were calibrated against the CX3
machine used at the Cleveland Clinic laboratory by using the re-
gression formula y = 0.9954x + 0.0208. We evaluated changes in
eGFR as both a continuous outcome and a binary outcome in
which accelerated decline of eGFR was defined as .2 mL 
min21  1.73 m22 per year.
Urinary albumin and creatinine concentrations were measured
at visit 1 and 3. We evaluated changes in the urinary albumin to
creatinine ratio (UACR) as a continuous outcome and as a binary
outcome capturing clinically significant progression of albu-
minuria. We defined this progression as attainment of micro-
albuminuria (UACR  30 mg/g) for participants without
microalbuminuria at visit 1 or as a 25% increase in UACR for
participants whose UACR at visit 1 was 30 mg/g. For sensi-
tivity analyses, we used an alternative definition for micro-
albuminuria, using sex-specific cutoffs of 17 mg/g in males
and 25 mg/g in females (8–10).
Predictors
Diet was assessed at the baseline visit via a food-frequency
questionnaire asking participants to self-report their usual eating
habits over the previous year (11). Sugar-sweetened beverage
consumption was quantified from an item listing “regular soft
drinks, soda, sweetened mineral water (not diet), nonalcoholic
beer.” We were not able to subtract out nonalcoholic beer from
this question and therefore assumed that consumption of non-
alcoholic beer was negligible. Frequency response options for
this questionnaire item were as follows: rare or never, 1–3 per/mo,
1/wk, 2–4/wk, 5–6/wk, 1/d, 2–3/d, 4–5/d, and6/d. According to
the exposure distribution, we collapsed these responses into 3
levels: ,1 sugar-sweetened beverage/wk, 1–6 sugar-sweetened
beverages/wk, and 1 sugar-sweetened beverage/d. We felt that
these categories captured significant degrees of exposure and
consisted of easily communicable levels of beverage intake. For
the sensitivity analysis, we also examined sugar-sweetened
beverage intake as a binary variable: participants who drank ,1
sugary beverage/d compared with participants who drank 1
sugary beverage/d. We had no data on sugar-sweetened beverage
consumption at points other than the baseline visit.
Other baseline characteristics included demographics (age,
sex, race, and education status), lifestyle and dietary character-
istics (intentional exercise, tobacco use, daily sodium intake, daily
phosphorus intake, daily protein intake, and daily caloric intake),
medical history (diabetes, hypertension, and dyslipidemia),
physical examination findings (body mass index and systolic and
diastolic blood pressure), and laboratory values (LDL and HDL
cholesterol, triglycerides, and glucose). Education level was di-
chotomized by high school graduation status. Smoking was di-
chotomized by current use. Diabetes was defined by medication
use or a fasting glucose concentration 126 mg/dL. Hyperten-
sion was defined as systolic pressure 140 mm Hg, diastolic
pressure 90 mm Hg, or use of antihypertensive medication.
Dyslipidemia was defined as low HDL (,40 mg/dL in men,,50
mg/dL in women), elevated LDL (.130 mg/dL in nonpatients
with diabetes, .100 mg/dL in patients with diabetes), elevated
triglycerides (.250 mg/dL), or use of lipid-lowering medication.
Statistical analyses
Baseline characteristics by categories of sugar-sweetened
beverage consumption were described as mean, median, or
percentage values; the distribution of these characteristics was
tested by one-factor analysis of variance. Linear regression
models were created by using the categories of sugar-sweetened
beverage consumption to predict the average annual change in
eGFR and UACR (ie, estimated slope from available eGFR and
UACR values) for each individual from examinations 1 and 3.
Annualized changes in eGFR and UACR were calculated by
using a least-squares regression slope. For the dichotomized
outcomes of eGFR decline (incorporating data from examinations
1, 3, and 4) and UACR increase, defined above, logistic regression
models were used. Covariates were entered into the models as
potential confounders if they were identified as antecedents of
both kidney disease and sugar-sweetened beverage consumption.
Three consecutive models were constructed for each kidney
decline endpoint: an unadjusted model; a minimally adjusted
model (model 1) including age, sex, race (4 categories), and
baseline kidney function; and a fully adjusted model (model 2)
including age, sex, race, education, smoking status, BMI, hy-
pertension, diabetes mellitus, dyslipidemia, total caloric intake,
total phosphorus intake, total protein intake, and baseline kidney
function. Because of its nonparametric distribution, baseline
UACR was logarithmically transformed in these analyses.
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Sensitivity analyses were performed excluding diabetic sub-
jects, without adjustment for baseline kidney function, and
substituting continuous values of systolic and diastolic blood
pressure for the binary covariable of hypertensive status. In
addition, for comparison and to potentially isolate the effect of
the high-fructose corn syrup used to sweeten regular sodas, all
analyses were repeated by using diet soda consumption, rather
than sugar soda consumption, as the exposure of interest. Diet
soda intakewas quantified from the food-frequency questionnaire
item listing “diet soft drinks, unsweetened mineral water.”
Two-sided hypotheses tests with a 5% type I error were
adopted for all statistical inferences. S-Plus (release 8.0; In-
sightful Inc, Seattle, WA) and SPSS statistical software (release
15.0.1; SPSS Inc, Chicago, IL) were used for the analyses.
RESULTS
Of 6814 MESA participants, 447 met our prespecified criteria
for CKD, with a baseline eGFR,60 mL  min21  1.73 m22 that
remained ,60 mL  min21  1.73 m22 at visit 3 and/or visit 4.
Of these CKD subjects, 294 (66%) drank ,1 sugar-sweetened
beverage/wk, 108 (24%) drank between 1 and 6 sweetened
beverages/wk, and 45 (10%) drank 1 sugar-sweetened
beverage/d (Table 1). In comparison, 271 (61%) drank ,1 diet
soda/wk, 95 (21%) drank between 1 and 6 diet sodas/wk, and 79
(18%) drank 1 diet soda/d.
Participants who drank 1 sugar-sweetened beverage/d, the
highest exposure category, were more likely to be male, African
American or Hispanic, and current smokers than were partic-
ipants who drank ,1 sugary beverage/wk. Although there was
no differences in mean body mass index across exposure groups,
participants who consumed more sugar-sweetened beverages
had significantly greater sodium, protein, and total calorie in-
takes. Hypertensive status did not differ between exposure
groups, whereas patients with diabetes were most represented in
the group with the least amount of sugary beverage consump-
tion. The 3 exposure groups did not significantly differ with
regard to baseline kidney function as determined by serum
creatinine, eGFR, or UACR.
Change in estimated GFR
Of all participants identified with CKD, the mean (6 SD)
baseline eGFR was 52 6 6 mL  min21  1.73 m22. The mean
(6SD) decline in eGFR during the 5-y study period was
0.95 (63.12) mL  min21  1.73 m22 per year for all CKD
TABLE 1
Baseline characteristics of the study population1
Sugar-sweetened beverage intake
,1/wk (n = 294) 1–6/wk (n = 108) 7/wk (n = 45)
Age (y) 70 6 82 67 6 9 67 6 9
Female [n (%)] 195 (66) 56 (52) 21 (49)
Race-ethnicity [n (%)]
White 175 (60) 55 (51) 22 (51)
Asian 40 (14) 8 (7) 0 (0)
Black 40 (14) 27 (25) 9 (21)
Hispanic 39 (13) 18 (17) 12 (28)
High school education and higher [n (%)] 242 (83) 94 (87) 34 (79)
BMI (kg/m2) 28.6 6 5.2 28.3 6 5.2 29.2 6 5.8
Hypertension [n (%)]3 202 (69) 68 (63) 27 (63)
SBP (mm Hg) 136 6 22 132 6 21 137 6 21
DBP (mm Hg) 71 6 10 71 6 11 74 6 11
Diabetes [n (%)] 54 (18) 12 (11) 3 (7)
Current smokers [n (%)] 13 (4) 12 (11) 4 (9)
Dyslipidemia [n (%)]4 213 (72) 86 (80) 27 (63)
Low-density lipoprotein (mg/dL) 118 6 31 120 6 31 112 6 37
High-density lipoprotein (mg/dL) 53 6 15 50 6 13 45 6 13
Triglycerides (mg/dL) 122 (85–170)5 129 (88–190) 135 (100–173)
Use of lipid-lowering medication [n (%)] 86 (29) 34 (32) 5 (12)
Sodium intake (mg/d) 1660 (1202–2455) 2255 (1534–2722) 2593 (1713–3208)
Phosphorus intake (mg/d) 837 (607, 1224) 895 (667–1245) 1069 (827–1402)
Protein intake (g/d) 57 6 27 60 6 22 68 6 32
Total energy intake (kcal/d) 1251 (916–1704) 1570 (1216–1859) 1926 (1579–2311)
Intentional exercise (MET min/wk) 994 (315–2460) 1020 (171–1890) 420 (0–1125)
Baseline serum creatinine (mg/dL) 1.26 6 0.25 1.34 6 0.28 1.33 6 0.25
Baseline eGFR (mL  min21  1.73 m22) 53 6 6 53 6 7 53 6 6
Baseline albumin:creatinine ratio (mg/g) 6.2 (3.5–16.1) 7.2 (3.7–21.3) 4.6 (2.9–30.3)
1 SBP, systolic blood pressure; DBP, diastolic blood pressure; MET, metabolic equivalent task; eGFR, estimated glomerular filtration rate.
2 Mean 6 SD (all such values).
3 Defined as SBP  140 mm Hg, DBP  90 mm Hg, or use of blood pressure–lowering medication.
4 Defined as low HDL cholesterol (,40 mg/dL in men, ,50 mg/dL in women), elevated LDL cholesterol (.130 mg/dL in nonpatients with diabetes,
.100 mg/dL in patients with diabetes), elevated triglyceride (.250 mg/dL), or use of lipid-lowering medication.
5 Median; interquartile range (all such values).
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participants. In univariate and multivariate analyses, the yearly
change in eGFR was not related to a subject’s degree of sugar-
sweetened beverage consumption (Figure 1, Table 2). A binary
outcome for accelerated decline of eGFR, defined as .2 mL 
min21  1.73 m22 per year, showed a similar lack of association.
With participants who drank ,1 sugary beverage/wk as a ref-
erent, the multivariate odds ratios for rapid GFR decline were
1.17 (0.70, 1.97; P = 0.6) for participants who drank 1–6 sugary
beverages/wk and 0.62 (0.27, 1.41; P = 0.3) for participants who
drank 1 sugary beverage/d.
Change in urinary albumin excretion
The median baseline UACR for participants with CKDwas 6.3
[interquartile range (IQR) = 3.5, 17.6] mg/g. By visit 3, the
UACR increased on average by 6.3 6 94 mg/g for these par-
ticipants. In univariate and multivariate models, the amount of
sugar-sweetened beverage consumption was not associated with
changes in UACR (Figure 2, Table 3). A binary outcome for
clinically significant progression of albuminuria—defined as
attainment of microalbuminuria (UACR  30 mg/g) for par-
ticipants without microalbuminuria at visit 1 or as a 25% in-
crease in UACR for participants whose UACR at visit 1 was
30 mg/g—further confirmed this lack of association. With
participants who drank,1 sugary beverage/wk as a referent, the
multivariate odds ratios for albuminuria progression was 1.48
(95% CI: 0.73, 3.00; P = 0.3) for participants who drank 1–6
sugary beverages/wk and 1.51 (95% CI: 0.49, 4.62; P = 0.5) for
participants who drank 1 sugary beverage/d. Sensitivity anal-
yses using sex-specific microalbuminuria cutoffs and excluding
FIGURE 1. Mean changes in estimated glomerular filtration rate (eGFR) (A) and the clinically significant decline in eGFR (B) after sugar-sweetened and
diet beverage intakes per week among participants with chronic kidney disease. The data reflect univariate relations; in multivariate analyses, point estimates
for diet and regular soda were not significantly different. The bars in panel A reflect 95% CIs.
TABLE 2
Association of sugar-sweetened beverage intake with rate of decline in kidney function between visits 1, 3, and 41
Kidney function
Unadjusted Model 12 Model 23
Value P Value P Value P
Continuous DeGFR4,5
Sugar-sweetened beverage intake
,1/wk (n = 294) Reference Reference Reference
1–6/wk (n = 108) 0.04 (20.66, 0.73) 0.9 0.05 (20.64, 0.73) 0.9 20.06 (20.75, 0.64) 0.9
7/wk (n = 45) 0.03 (20.97, 1.04) 0.9 0.12 (20.87, 1.11) 0.8 0.29 (20.78, 1.37) 0.6
Rapid decline: DeGFR , 22.006
Sugar-sweetened beverage intake
,1/wk (n = 93) Reference Reference Reference
1–6/wk (n = 37) 1.12 (0.70, 1.79) 0.6 1.07 (0.65, 1.74) 0.8 1.17 (0.70, 1.97) 0.6
7/wk (n = 12) 0.83 (0.41, 1.69) 0.6 0.72 (0.34, 1.52) 0.4 0.62 (0.27, 1.41) 0.3
1 DeGFR, change in estimated glomerular filtration rate.
2 Adjusted for baseline eGFR, age, sex, and race.
3 Adjusted for baseline eGFR, age, sex, race, education, field center, current smoking, BMI, hypertension, diabetes mellitus, dyslipidemia, phosphorus
intake, protein intake, and total calorie intake.
4 per mL  min21  1.73 m22 per year.
5 Values are b-coefficients (95% CIs).
6 Values are odds ratios (95% CIs).
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diabetic subjects yielded virtually identical estimates. Because
UACR was measured only twice in this study, a regression to the
mean phenomenon could not be ruled out.
DISCUSSION
In this study, we observed no association between a higher
consumption of sugar-sweetened beverages and progression of
established CKD. In contrast with previously published reports
that a high intake of sugar sodas was associated with renal injury,
manifested as elevated serum creatinine and presence of albu-
minuria (3, 4), we found no link between the degree of sugar-
sweetened beverage intake and changes in either the estimated
GFR or UACR. In fact, sugary beverage consumption showed
a lack of association with CKD progression similar to diet soda
intake (Figures 1 and 2). Our results suggest that higher con-
sumption of sugar-sweetened drinks may not pose an additional
risk to already damaged kidneys.
This study, to our knowledge, is the first to examine whether
heavy consumption of sugar-sweetened beverages is an important
determinant of how renal function progresses in CKD. This
question is important for 2 principal reasons. First, given the
variable and unpredictable course of CKD, dietary factors that
can aggravate preexisting renal injuries should clearly be avoided
FIGURE 2. Mean changes in the urinary albumin to creatinine ratio (UACR) (A) and the clinically significant progression of UACR (B) after sugar-
sweetened and diet beverage intake per week. Significant progression was defined as a UACR ,30 mg/g at examination 1 and 30 mg/g at examination 3 or
a UACR.30 mg/g at examination 1 with an increase in UACR of 25%. The data reflect univariate relations; in multivariate analyses, point estimates for diet
and regular soda were not significantly different. The patterns in panel A are highly influenced by comorbidities such as diabetic and hypertensive status. The
bars in panel A reflect 95% CIs.
TABLE 3
Association of sugar-sweetened beverage intake with increase in urinary albumin excretion between visits 1 and 31
UACR
Unadjusted Model 12 Model 23
Value P Value P Value P
Continuous DUACR
Sugar-sweetened beverage intake4
,1/wk (n = 294) Reference Reference Reference
1–6/wk (n = 108) 22.88 (217.21, 11.44) 0.7 20.98 (215.65, 13.69) 0.9 20.67 (215.74, 14.40) 0.9
7/wk (n = 45) 22.11 (222.91, 18.70) 0.8 0.27 (220.94, 21.49) 1.0 20.39 (223.60, 22.83) 1.0
UACR ,30 mg/g at exam 1 and 30 mg/g at exam 3 or
UACR .30 mg/g at exam 1 that increased 25%5
Sugar-sweetened beverage intake
,1/wk (n = 39) Reference Reference Reference
1–6/wk (n = 19) 1.31 (0.71, 2.41) 0.4 1.44 (0.74, 2.81) 0.3 1.48 (0.73, 3.00) 0.3
7/wk (n = 7) 1.26 (0.53, 3.03) 0.6 1.28 (0.48, 3.43) 0.6 1.51 (0.49, 4.62) 0.5
1 UACR, urinary albumin to creatinine ratio; DUACR, change in UACR.
2 Adjusted for baseline UACR, age, sex, race.
3 Adjusted for baseline UACR, age, sex, race, education, field center, current smoking, BMI, hypertension, diabetes mellitus, dyslipidemia, phosphorus
intake, protein intake, and total calorie intake.
4 Values are b-coefficients (95% CIs).
5 Values are odds ratios (95% CIs).
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in this disease state. The findings of this study suggest that sugar-
sweetened beverages do not fit this bill. This was an unexpected
result, not only because of the findings of previous studies on
sugary beverage intake and kidney disease, but also because of
presumed associations between regular soda use and higher rates
of obesity, hypertension, and diabetes (12–14).
Second, in examining whether sugar-sweetened beverages
influence the rate of CKD progression, we also indirectly ex-
amined the role of high-fructose corn syrup, the sweetener for
these beverages, in such progression. The controversy over the
potential dangers of high-fructose corn syrup has been playing
out not only in the medical literature (15–20), but also in the
mainstream media, including advertising campaigns funded by
the corn-producing industry (www.sweetsurprise.com). Oppo-
nents of high-fructose corn syrup voice concern over fructose’s
unique metabolism driving the synthesis of uric acid. In animal
models, fructose-associated hyperuricemia produces a metabolic
syndrome associated with glomerular hypertension, renal hy-
pertrophy, cortical vasoconstriction, and arteriolopathy of renal
vasculature (21, 22). Defenders of high-fructose corn syrup point
out that this sweetener consists of ’40–55% fructose (the other
components being glucose and readily hydrolyzable polymers of
glucose); therefore, findings from animal and human studies that
use 100% fructose formulations are not applicable to high-
fructose corn syrup (23). Indeed, in our study, sugar-sweetened
beverages showed the same lack of association with CKD pro-
gression as diet sodas, which argues against a causative role for
high-fructose corn syrup.
Our results must be interpreted with caution, however. The
lack of association seen in this study may be due to our starting
population, and the findings of this study should not be ex-
trapolated to the non-CKD population. Whereas we showed that
sugar-sweetened beverages do not seem to influence the pro-
gression of preexistent CKD in this specific subcohort, these
results should not be viewed as definitive evidence that these
beverages do not pose any risk to kidney function. The previous
studies on soda consumption and renal dysfunction cited above
could, in light of our current findings, be interpreted as indicative
of the harms of sugary soda being limited to incipient kidney
disease, whereas our results show that these sweetened beverages
do not pose additional risk in already dysfunctional kidneys. In
short, once the kidney has suffered a chronic insult, a salubrious
intervention such as soda restriction may not be able to yield any
substantial benefit. In addition, our analysis only looked at kidney
function per se and not the consequences of reduced kidney
function, such as anemia, abnormal bone and mineral metabo-
lism, premature cardiovascular disease, and reduced quality of
life, which theoretically could be affected by soda intake in-
dependent of its effects on kidney function.
The strengths of our study include its use of a racially diverse,
community-based population that should permit generalizability
to a wide array of patients. The cohort, on average, experienced
a decrease in eGFR of ’1 mL  min21  1.73 m22 per year,
which likely places this group of individuals in the healthier
spectrum of patients treated in routine clinical practice. MESA
collected detailed characteristics of its participants, including
baseline risk factors and comorbidities, which allowed for ap-
propriate statistical adjustments and, again, confirmed that its
participants were comparable with patients in the general pop-
ulation. Notably, MESA collected data on total calorie intake
and physical activity—confounding variables that have been
postulated as the true causes of the epidemic of obesity in the
high-fructose corn syrup era (24). We also believe that our
definition of CKD, based on multiple serum creatinine meas-
urements, ensured that our subjects truly represented patients
with renal dysfunction. This makes our results particularly ap-
plicable for practicing nephrologists, who generally see patients
once kidney injury is established. Therefore, dietary inter-
ventions that slow the progression of established CKD, rather
than prevent incident CKD, are more pragmatic lifestyle mod-
ifications for nephrologists to stress on their patients.
This study had many limitations. First, our exposure of interest
was based on participants’ dietary recall; thus, measurement error
was inevitable. For example, the daily sodium intakes reported by
these same participants (Table 1) suggest underreporting of salt
consumption, particularly among participants who drank ,1
sugary beverage/wk; this may portend similar underreporting of
sugary beverage intake and a potential bias toward a null effect.
In addition, our exposure is based on a survey question asking
about “regular soft drinks, soda, sweetened mineral water (not
diet), nonalcoholic beer.” We were not able to subtract out from
this category consumption of nonalcoholic beer and therefore
may have overestimated the degree of sugar-sweetened beverage
intake for some subjects. It should be noted that our exposure
category of 1 sugar-sweetened beverage/d is slightly lower
than the highest category of exposure used in the analysis by
Shoham et al (4), which was 2 sugary drinks/d. There were too
few participants in the MESA cohort with this level of exposure
to permit this categorization.
Second, we focused on the baseline intake of sugar-sweetened
beverages and were not able to evaluate whether participants’
intake of these beverages changed during the study period.
Theoretically, this could have biased results toward the null if the
group with the highest exposure cut down their beverage intake as
a result of participation in this study. Other variables that may
have changed during the study period and that could have affected
renal function include blood pressure and diabetes status, use of
medications (particularly renin-angiotensin system blocking
drugs), and changes in salt intake. In this relatively healthy
cohort, we assumed that access to health care and use of ap-
propriate therapeutic interventions to address these factors was
relatively equal across exposure groups.
Third, MESA did not measure uric acid concentrations to
allow an exploration of whether sugary beverage intake led to
a higher risk of hyperuricemia, as was suggested recently in
a cross-sectional analysis of data from the third National Health
and Nutrition Examination Survey (25). Given recent reports that
elevated uric acid concentrations are an independent risk factor
for incident CKD and progression of established CKD (26–28),
we may have been able to see an association between sugar-
sweetened beverage consumption and CKD progression in
subgroup analyses focused on uric acid concentrations.
Finally, despite a relatively large starting population of almost
7000 participants, our strict definition for CKD reduced our study
sample to 447 subjects, limiting our power to detect statistically
significant differences among groups. In post hoc power analysis,
however, we still had 80% power to detect a change of 1.5 mL 
min21  1.73 m22 in eGFR and a change of 12.5 mg/g in UACR
over the study period. We do not feel that the lack of association
shown here was due to type II error. Our point estimates show
SUGAR-SWEETENED BEVERAGES AND CKD PROGRESSION 1177
relative concordance between univariate and multivariate anal-
yses as well as an absence of dose response. In addition, the
results of our varied sensitivity analyses showed essentially an
identical lack of association.
We believe that our results should be primarily viewed as a call
for repeated investigations into the role of sugar soda in the
development and progression of CKD, ideally studies using
larger starting populations with varying degrees of kidney
function. We do not, by any means, intend these findings to be
a justification for unbridled consumption of sugar sodas by
individuals with and without CKD. Rather, we intend our study to
be an important addition to the large and still-growing body of
literature surrounding the potential health consequences of sugar
soda and high-fructose corn syrup, which is based principally on
observational studies such as this one. Our negative study
results—subject to the same potential sources of error (bias,
chance, and confounding) as other positive study results—should
be used to further inform, rather than end, the heated debate
regarding this important public health issue.
In conclusion, sugar-sweetened beverage consumption was not
associated with disease progression among adults with pre-
existent CKD in this multiethnic cohort. The lack of association
between sugary beverage consumption and CKD progression,
similar to that seen with diet soda intake, does not support the
hypothesis that the fructose used to sweeten these drinks poses an
additional risk to already damaged kidneys.
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